1. 109P Impact of anti-drug antibody (ADA) on naxitamab efficacy and safety. (December 2022) Authors: Kushner, B.; Chan, G.C.; Morgenstern, D.A.; Amoroso, L.; Nysom, K.; Faber, J.; Wingerter, A.; Bear, M.; Rubio San Simon, A.; Tornøe, K.; Sørensen, P.S.; Mora, J. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 62MO Naxitamab pivotal clinical trial planned interim analysis of PFS and OS in patients with relapsed or refractory high-risk neuroblastoma. (December 2022) Authors: Mora, J.; Chan, G.C.; Morgenstern, D.A.; Amoroso, L.; Nysom, K.; Faber, J.; Wingerter, A.; Bear, M.; Rubio San Simon, A.; Tornøe, K.; Sørensen, P.S.; Kushner, B. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗